Medical Communications
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023 Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Angiex’s IND application for AGX101 cleared by FDA
November 3, 2023 Medical Communications AGX101, Angiex, FDA, Oncology
FDA approves Phathom Pharmaceuticals’ Voquezna for erosive GERD
November 3, 2023 Medical Communications Erosive GERD, FDA, Gastrointestinal tract, Phathom Pharmaceuticals, Voquezna
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
November 2, 2023 Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B
Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment
October 31, 2023 Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023 Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023 Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment
October 27, 2023 Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023 Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
FDA approves Servier Pharmaceuticals’ new MDS therapy
October 25, 2023 Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes
AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA
October 24, 2023 Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA
GSK and Zhifei partner for shingles vaccine promotion in China
October 9, 2023 Medical Communications GSK, Immunology, Shingrix, Vaccine, Zhifei, shingles
FDA accepts Sun Pharma’s NDA for deuruxolitinib
October 6, 2023 Medical Communications Dermatology, FDA, NDA, SUun Pharma, deuruxolitinib
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023 Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
WHO recommends new vaccine for prevention of malaria in children
October 3, 2023 Medical Communications Immunology, Vaccine, WHO, malaria, malaria vaccine
Latest content
